Phenotypes and clinical significance of circulating CD4+CD25+ regulatory T cells (Tregs) in patients with acute-on-chronic liver failure (ACLF)

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Yang, Jiezuan ^a   Yi, Ping ^a   Wei, Li ^a   Xu, Zherong ^a   Chen, Yunbo ^a   Tang, Lingling ^a   Li, Lanjuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ARTICLE; BETA CHAIN; BLOOD ANALYSIS; CD4+ CD25+ T LYMPHOCYTE; CELL SELECTION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GENE SEQUENCE; HUMAN; LYMPHOCYTE FUNCTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN MOTIF; REGULATORY T LYMPHOCYTE;

ADULT; ANTIGENS, CD4; CENTRIFUGATION; END STAGE LIVER DISEASE; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 84866178515     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-193     Document Type: Article

References (40)

1. Lanini S, Puro V, Lauria FN, Fusco FM, Nisii C, Ippolito G. Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Med 2009, 7:15. 10.1186/1741-7015-7-15, 2676313, 19356228.
2. Wiersma ST, McMahon B, Pawlotsky JM, Thio CL, Thursz M, Lim SG, Ocama P, Esmat G, Maimuna M, Bell D, Vitoria M, Eramova I, Lavanchy D, Dusheiko G. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011, 31:755-761. 10.1111/j.1478-3231.2010.02373.x, 21645206.
3. Xu Z, Ren X, Liu Y, Li X, Bai S, Zhong Y, Wang L, Mao P, Wang H, Xin S, Wong VW, Chan HL, Zoulim F, Xu D. Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol 2011, 46:391-400. 10.1007/s00535-010-0315-4, 20848146.
4. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002, 20:252-261. 10.1159/000047017, 11867872.
5. Jung O, Asbe-Vollkopf A, Betz C, Caspary W, Geiger H, Faust D. Long-term therapy of acute chronic liver failure to successful transplantation with an extracorporeal liver support system. Z Gastroenterol 2007, 45:21-24. 10.1055/s-2006-927385, 17236117.
6. Chen Z, Wen T, Zeng Y, Wang L, Lu JJ, Gong S, Tan H, Feng P, Li B, Zhao J, Wang W, Xu M, Yang J, Wu H, Yan L. A single institution experience with living donor liver transplantation for acute-on-chronic hepatitis b liver failure. Hepatogastroenterology 2011, 58:1286-1290.
7. Bahirwani R, Shaked O, Bewtra M, Forde K, Reddy KR. Acute-on-chronic liver failure before liver transplantation: impact on posttransplant outcomes. Transplantation 2011, 92:952-957. 10.1097/TP.0b013e31822e6eda, 21869735.
8. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005, 6:353-360.
9. Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008, 123:57-65. 10.1111/j.1365-2567.2007.02691.x, 2433275, 17764450.
10. Nan XP, Zhang Y, Yu HT, Li Y, Sun RL, Wang JP, Bai XF. Circulating CD4 + CD25high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection. Viral Immunol 2010, 23:63-70. 10.1089/vim.2009.0061, 20121403.
11. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao JM, Zhang B, Shi M, Ding X, Tang Z, Fu YX, Wang FS. Circulating and liver resident CD4 + CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006, 177:739-747.
12. Wang LW, Chen H, Gong ZJ. High mobility group box-1 protein inhibits regulatory T cell immune activity in liver failure in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2010, 9:499-507.
13. Miles JJ, Douek DC, Price DA. Bias in the alphabeta T-cell repertoire: implications for disease pathogenesis and vaccination. Immunol Cell Biol 2011, 89:375-387. 10.1038/icb.2010.139, 21301479.
14. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009, 3:269-282. 10.1007/s12072-008-9106-x, 2712314, 19669378.
15. Liver Failure and Artificial Liver Group Chinese Society of Infectious Diseases Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group Chinese Society of Hepatology Chinese Medical Association Diagnostic and treatment guidelines for liver failure. Zhonghua Gan Zang Bing Za Zhi 2006, 14:643-646. Liver Failure and Artificial Liver Group Chinese Society of Infectious Diseases Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group Chinese Society of Hepatology Chinese Medical Association.
16. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E, Bach J, Geier A, Purucker EA, Gressner AM, Matern S, Lammert F. Patients with acute on chronic liver failure display " sepsis-like" immune paralysis. J Hepatol 2005, 42:195-201.
17. Chen Y, Li X, Ye B, Yang X, Wu W, Chen B, Pan X, Cao H, Li L. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res 2011, 91:23-31. 10.1016/j.antiviral.2011.04.008, 21549152.
18. Pan XB, Wei L, Han JC, Gao Y. Cellular chromosome DNA interferes with fluorescence quantitative real-time PCR detection of HBV DNA in culture medium. J Med Virol 2008, 80:47-52. 10.1002/jmv.21042, 18041004.
19. Yang JZ, Li MW, Wang JG, Lu HF, Yao XS, He JQ, Li LJ. Rapid detection of clonal expansion of T-cell receptor-beta gene in patients with HBV using the real-time PCR with DNA melting curve analysis. Hepatol Res 2010, 40:407-414. 10.1111/j.1872-034X.2009.00600.x, 20070405.
20. Yang J, He J, Lu H, Wei L, Li S, Wang B, Diao H, Li L. Molecular features of the complementarity determining region 3 motif of the T cell population and subsets in the blood of patients with chronic severe hepatitis B. J Transl Med 2011, 9:210. 10.1186/1479-5876-9-210, 3256121, 22152113.
21. Sing GK, Li D, Chen X, Macnaughton T, Lichanska AM, Butterworth L, Ladhams A, Cooksley G. A molecular comparison of T lymphocyte populations infiltrating the liver and circulating in the blood of patients with chronic hepatitis B: evidence for antigen-driven selection of a public complementarity-determining region 3 (CDR3) motif. Hepatology 2001, 33:1288-1298. 10.1053/jhep.2001.24026, 11343258.
22. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41:771-778. 10.1002/hep.20649, 15791617.
23. Tsunemi S, Iwasaki T, Imado T, Higasa S, Kakishita E, Shirasaka T, Sano H. Relationship of CD4 + CD25+ regulatory T cells to immune status in HIV-infected patients. AIDS 2005, 19:879-886. 10.1097/01.aids.0000171401.23243.56, 15905668.
24. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007, 361:141-148. 10.1016/j.virol.2006.11.018, 17184802.
25. Garcia-Castillo H, Barros-Nunez P. Detection of clonal immunoglobulin and T-cell receptor gene recombination in hematological malignancies: monitoring minimal residual disease. Cardiovasc Hematol Disord Drug Targets 2009, 9:124-135. 10.2174/187152909788488627, 19519371.
26. Marrack P, Kappler J. Positive selection of thymocytes bearing alpha beta T cell receptors. Curr Opin Immunol 1997, 9:250-255. 10.1016/S0952-7915(97)80144-6, 9099796.
27. Miqueu P, Guillet M, Degauque N, Dore JC, Soulillou JP, Brouard S. Statistical analysis of CDR3 length distributions for the assessment of T and B cell repertoire biases. Mol Immunol 2007, 44:1057-1064. 10.1016/j.molimm.2006.06.026, 16930714.
28. Okajima M, Wada T, Nishida M, Yokoyama T, Nakayama Y, Hashida Y, Shibata F, Tone Y, Ishizaki A, Shimizu M, Saito T, Ohta K, Toma T, Yachie A. Analysis of T cell receptor Vbeta diversity in peripheral CD4 and CD8 T lymphocytes in patients with autoimmune thyroid diseases. Clin Exp Immunol 2009, 155:166-172. 10.1111/j.1365-2249.2008.03842.x, 2675246, 19040601.
29. Du JW, Gu JY, Liu J, Cen XN, Zhang Y, Ou Y, Chu B, Zhu P. TCR spectratyping revealed T lymphocytes associated with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2007, 48:1618-1627. 10.1080/10428190701474357, 17701594.
30. Zaccone P, Cooke A. Harnessing CD8(+) regulatory T cells: therapy for type 1 diabetes?. Immunity 2010, 32:504-506. 10.1016/j.immuni.2010.04.009, 20412762.
31. Sharabi A, Mozes E. Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases. Immunotherapy 2009, 1:385-401. 10.2217/imt.09.2, 20635958.
32. Davis JL, Theoret MR, Zheng Z, Lamers CH, Rosenberg SA, Morgan RA. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin Cancer Res 2010, 16:5852-5861. 10.1158/1078-0432.CCR-10-1280, 3058233, 21138872.
33. Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, Ji Y, Chinnasamy D, Kaiser AD, Hinrichs CS, Klebanoff CA, Scott CD, Gattinoni L, Morgan RA, Rosenberg SA, Restifo NP. Genetic engineering of murine CD8(+) and CD4(+) T cells for preclinical adoptive immunotherapy studies. J Immunother 2011, 34:343-352. 10.1097/CJI.0b013e3182187600, 3100770, 21499127.
34. Bendle GM, Haanen JB, Schumacher TN. Preclinical development of T cell receptor gene therapy. Curr Opin Immunol 2009, 21:209-214. 10.1016/j.coi.2009.02.007, 19321326.
35. Wang QJ, Hanada K, Feldman SA, Zhao Y, Inozume T, Yang JC. Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. J Immunol Methods 2011, 366:43-51. 10.1016/j.jim.2011.01.002, 3061346, 21255579.
36. Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, Zheng Z, Restifo NP, Rosenberg SA, Morgan RA. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol 2010, 184:5988-5998. 10.4049/jimmunol.1000189, 20427771.
37. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129. 10.1126/science.1129003, 2267026, 16946036.
38. Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 2011, 55:103-110. 10.1016/j.jhep.2010.10.025, 21145860.
39. Picarda E, Anegon I, Guillonneau C. T-cell receptor specificity of CD8(+) tregs in allotransplantation. Immunotherapy 2011, 3:35-37. 10.2217/imt.11.37, 21524168.
40. Adeegbe D, Matsutani T, Yang J, Altman NH, Malek TR. CD4(+) CD25(+) Foxp3(+) T regulatory cells with limited TCR diversity in control of autoimmunity. J Immunol 2010, 184:56-66. 10.4049/jimmunol.0902379, 2949410, 19949075.